FDA Approves Simtriyo, a First-in-Class Non-Stimulant ADHD Drug

The FDA has approved Simtriyo (centanafadine), a first-in-class non-stimulant treatment for attention-deficit/hyperactivity disorder — the first new mechanism in the field in years.

Cleared on July 24, 2026, the once-daily extended-release capsule from Otsuka is approved for adults and children aged 6 and older weighing at least 20 kg.

A new mechanism

Simtriyo is the first drug in a class called NDSRI — a norepinephrine, dopamine and serotonin reuptake inhibitor. Blocking reuptake of all three at once raises their availability in brain pathways governing attention and behaviour.

No previously approved ADHD medication works on all three simultaneously, which is what makes it first-in-class.

What reuptake inhibition does

Neurons release neurotransmitters into the synapse and then recover them through transporter proteins, which ends the signal and recycles the molecule. Blocking a transporter leaves more neurotransmitter in the synapse for longer, extending the signal.

Existing ADHD treatments already use this. The established non-stimulant blocks norepinephrine reuptake selectively; stimulants block both norepinephrine and dopamine transporters and additionally cause release of stored neurotransmitter.

The addition here is serotonin, and it is the genuinely novel element. Serotonin is not conventionally central to ADHD models, which focus on norepinephrine and dopamine in the prefrontal cortex, but it modulates impulsivity and emotional regulation — features that trouble many patients and that existing drugs address indirectly at best.

Why the stimulant distinction matters

The mechanistic difference from stimulants explains the different profile.

Stimulants not only block transporters but reverse them, actively pumping stored dopamine out of the neuron. That produces a rapid rise in dopamine, which underlies both their fast onset and their abuse potential — the speed of the increase, rather than the increase itself, is what produces reinforcing effects.

Reuptake inhibition alone raises levels more gradually and depends on the neuron firing normally. Onset is slower, typically over weeks rather than within an hour, and the reinforcing effect is largely absent.

Which is the trade-off in plain terms: less immediate effect, and less scheduling burden, misuse concern and diversion risk.

The evidence

Approval was based on four Phase 3 trials showing significant improvement in ADHD symptoms with acceptable tolerability across age groups.

Four trials spanning adults and children is a substantial package for this indication. Demonstrating effect in both populations matters because ADHD presents differently by age — hyperactivity dominates in children, inattention and executive difficulty in adults — and drugs do not always perform equivalently across that range.

Why non-stimulants are needed

ADHD care leans heavily on stimulants, which do not suit everyone and carry misuse concerns.

The reasons patients need alternatives are specific. Some experience appetite suppression, sleep disruption, or increases in heart rate and blood pressure that make stimulants unsuitable. Some have co-occurring anxiety that stimulants worsen. Some have a history of substance use disorder making a controlled substance inadvisable. And a substantial minority simply do not respond adequately.

The existing non-stimulant options are fewer and generally less effective on average, so patients unsuited to stimulants have had a narrower and weaker set of choices.

What it changes

A non-stimulant with a genuinely new mechanism widens the options — particularly for patients who do not respond to or cannot take existing drugs.

Whether it proves as effective as stimulants is a separate question the approval does not answer, since the trials establish superiority to placebo rather than comparability to the standard.

Why the stimulant shortage sharpened the need

The approval lands after several years in which access to standard ADHD treatment was repeatedly disrupted, which changes how a non-stimulant alternative is valued.

Shortages of stimulant medications persisted across multiple countries, driven by a combination of increased diagnosis and prescribing, manufacturing constraints, and — in the United States — production quotas set by regulators for controlled substances, which cannot be raised quickly in response to demand.

Patients experienced that as pharmacies without stock, forced switching between formulations, and interruptions in treatment for a condition where interruption has immediate functional consequences for work and school.

A non-controlled medication is not subject to production quotas at all, which removes one structural cause of that instability.

Prescribing patterns are shifting too

Adult ADHD diagnosis has risen substantially, and adults present differently from the children the original evidence base was built on — more inattention and executive difficulty, less overt hyperactivity, and more co-occurring anxiety and mood disorder.

That co-occurrence matters for drug choice. Stimulants can worsen anxiety in some patients, which is a common reason for discontinuation, and a mechanism including serotonin may sit differently with that population.

Whether it does in practice is not established by trials measuring ADHD symptoms alone — but it is the question clinicians treating adults will be asking of it.

As with any new medication, effectiveness and side effects vary by person, and treatment should be guided by a clinician. General information, not medical advice.